155 related articles for article (PubMed ID: 2905003)
1. Mechanism of the lipid-mobilizing effect of alpha-2 adrenergic antagonists in the dog.
Taouis M; Berlan M; Montastruc P; Lafontan M
J Pharmacol Exp Ther; 1988 Dec; 247(3):1172-80. PubMed ID: 2905003
[TBL] [Abstract][Full Text] [Related]
2. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers.
Galitzky J; Taouis M; Berlan M; Rivière D; Garrigues M; Lafontan M
Eur J Clin Invest; 1988 Dec; 18(6):587-94. PubMed ID: 2906290
[TBL] [Abstract][Full Text] [Related]
3. Lipomobilizing effects of procaterol and yohimbine in the conscious dog: comparison of endocrinological, metabolic and cardiovascular effects.
Valet P; Taouis M; Tran MA; Montastruc P; Lafontan M; Berlan M
Br J Pharmacol; 1989 May; 97(1):229-39. PubMed ID: 2566353
[TBL] [Abstract][Full Text] [Related]
4. Lipolytic action of a new alpha-2 adrenergic antagonist of the piperazinopyrimidine family: RP 55462.
Saulnier-Blache JS; Taouis M; Dauzats M; Uzan A; Berlan M; Lafontan M
J Pharmacol Exp Ther; 1989 Dec; 251(3):1187-92. PubMed ID: 2574742
[TBL] [Abstract][Full Text] [Related]
5. [Evidence for an alpha 2-blocking property of nicergoline by using antilipolytic alpha-adrenoceptors from adipose tissue].
Carpéné C; Lafontan M; Berlan M
J Pharmacol; 1983; 14(1):57-66. PubMed ID: 6132024
[TBL] [Abstract][Full Text] [Related]
6. Alpha-2 adrenoceptors in lipolysis: alpha 2 antagonists and lipid-mobilizing strategies.
Lafontan M; Berlan M; Galitzky J; Montastruc JL
Am J Clin Nutr; 1992 Jan; 55(1 Suppl):219S-227S. PubMed ID: 1345885
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of lipolytic action of a new alpha-2 adrenergic antagonist of the piperazinopyrimidine family: RP 55462.
Saulnier-Blache JS; Taouis M; Dauzats M; Uzan A; Berlan M; Lafontan M
J Pharmacol Exp Ther; 1989 Dec; 251(3):1193-8. PubMed ID: 2481031
[TBL] [Abstract][Full Text] [Related]
8. Evidence for heterogeneity between pre- and postjunctional alpha-2 adrenoceptors using 9-substituted 3-benzazepines.
Daly RN; Sulpizio AC; Levitt B; DeMarinis RM; Regan JW; Ruffolo RR; Hieble JP
J Pharmacol Exp Ther; 1988 Oct; 247(1):122-8. PubMed ID: 2902209
[TBL] [Abstract][Full Text] [Related]
9. Alpha-2 adrenergic antilipolytic effect in dog fat cells: incidence of obesity and adipose tissue localization.
Berlan M; Carpene C; Lafontan M; Dang-Tran L
Horm Metab Res; 1982 May; 14(5):257-60. PubMed ID: 6284627
[TBL] [Abstract][Full Text] [Related]
10. Plasma catecholamine levels and lipid mobilization induced by yohimbine in obese and non-obese women.
Berlan M; Galitzky J; Riviere D; Foureau M; Tran MA; Flores R; Louvet JP; Houin G; Lafontan M
Int J Obes; 1991 May; 15(5):305-15. PubMed ID: 1885256
[TBL] [Abstract][Full Text] [Related]
11. Alpha 2-adrenergic receptor turnover in adipose tissue and kidney: irreversible blockade of alpha 2-adrenergic receptors by benextramine.
Taouis M; Berlan M; Lafontan M
Mol Pharmacol; 1987 Jan; 31(1):89-96. PubMed ID: 2880286
[TBL] [Abstract][Full Text] [Related]
12. Selective alpha-2 adrenoceptor blockade by SK&F 86466: in vitro characterization of receptor selectivity.
Hieble JP; DeMarinis RM; Fowler PJ; Matthews WD
J Pharmacol Exp Ther; 1986 Jan; 236(1):90-6. PubMed ID: 2867217
[TBL] [Abstract][Full Text] [Related]
13. Additional evidence for functional subclassification of alpha-2 adrenoceptors based on a new selective antagonist, SK&F 104856.
Hieble JP; Sulpizio AC; Edwards R; Chapman H; Young P; Roberts SP; Blackburn TP; Wood MD; Shah DH; Demarinis RM
J Pharmacol Exp Ther; 1991 Nov; 259(2):643-52. PubMed ID: 1682482
[TBL] [Abstract][Full Text] [Related]
14. Human fat cell alpha-2 adrenoceptors. I. Functional exploration and pharmacological definition with selected alpha-2 agonists and antagonists.
Galitzky J; Mauriege P; Berlan M; Lafontan M
J Pharmacol Exp Ther; 1989 May; 249(2):583-91. PubMed ID: 2566681
[TBL] [Abstract][Full Text] [Related]
15. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans.
Moro C; Crampes F; Sengenes C; De Glisezinski I; Galitzky J; Thalamas C; Lafontan M; Berlan M
FASEB J; 2004 May; 18(7):908-10. PubMed ID: 15033935
[TBL] [Abstract][Full Text] [Related]
16. Ability of SK&F 104078 and SK&F 104856 to identify alpha-2 adrenoceptor subtypes in NCB20 cells and guinea pig lung.
Gleason MM; Hieble JP
J Pharmacol Exp Ther; 1991 Dec; 259(3):1124-32. PubMed ID: 1684814
[TBL] [Abstract][Full Text] [Related]
17. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
Abdel-Zaher AO; Ahmed IT; El-Koussi AD
Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
[TBL] [Abstract][Full Text] [Related]
18. Interplay of alpha-2 and beta adrenoceptors in the control of free fatty acid release from bone marrow adipose tissue.
Tran MA; Lac DT; Berlan M; Lafontan M
J Pharmacol Exp Ther; 1984 Jul; 230(1):228-31. PubMed ID: 6086878
[TBL] [Abstract][Full Text] [Related]
19. Beta 3-adrenoceptors in dog adipose tissue: studies on their involvement in the lipomobilizing effect of catecholamines.
Galitzky J; Reverte M; Carpene C; Lafontan M; Berlan M
J Pharmacol Exp Ther; 1993 Jul; 266(1):358-66. PubMed ID: 8101220
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of RX 781094, mianserin, yohimbine, rauwolscine and prazosin in reversing clonidine inhibition of MIX-stimulated lipolysis in hamster isolated white fat cells.
Tan S; Curtis-Prior PB
Pharmacol Res Commun; 1984 May; 16(5):461-6. PubMed ID: 6204345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
